Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Keytruda with CisGem in Advanced Biliary Tract Cancer
NCT03260712Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jan 2020
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
A Phase 2 trial of pembrolizumab in biliary tract cancer (BTC), sponsored by European Organisation for Research and Treatment of Cancer. Started Jan 2020; status: completed.
02
Drugs
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT03260712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03260712.